Exodus Point Capital Management, LP Phathom Pharmaceuticals, Inc. Transaction History
Exodus Point Capital Management, LP
- $9.1 Billion
- Q3 2025
A detailed history of Exodus Point Capital Management, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 71,275 shares of PHAT stock, worth $1.05 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
71,275
Previous 15,146
370.59%
Holding current value
$1.05 Million
Previous $145,000
462.07%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PHAT
# of Institutions
150Shares Held
65.3MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million12.93% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...